Aquestive Therapeutics, Inc. (AQST)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 25M 50M 75M Q3 '21: 46.9M Q4 '21: 50.8M Q1 '22: 52M Q2 '22: 49.9M Q3 '22: 48.1M Q4 '22: 47.7M Q1 '23: 46.5M Q2 '23: 46.5M Q3 '23: 48.1M Q4 '23: 50.6M Q1 '24: 51.5M Q2 '24: 58.4M Q3 '24: 58.9M Q4 '24: 57.6M Q1 '25: 54.2M Q2 '25: 44.1M Q3 '25: 43.4M Q4 '25: 44.5M Q1 '26: 50.3M Q2 '26: 54.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 15M 30M 45M Q3 '20: 38.2M Q4 '20: 32.9M Q1 '21: 36.1M Q2 '21: 28.9M Q3 '21: 32.5M Q4 '22: 28.3M Q1 '23: 26.6M Q2 '23: 25.2M Q3 '23: 26.6M Q4 '23: 29.8M Q1 '24: 31M Q2 '24: 40M Q3 '24: 40.9M Q4 '24: 39.7M Q1 '25: 37.1M Q2 '25: 27M Q3 '25: 26.2M Q4 '25: 26M Q1 '26: 31.9M Q2 '26: 36.3M Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-75M -50M -25M 0 25M 50M 75M Q3 '21: -38.7M Q4 '21: -34.7M Q1 '22: -35.9M Q2 '22: -42.1M Q3 '22: -43M Q4 '22: -42.1M Q1 '23: -36.9M Q2 '23: -28.4M Q3 '23: -21.9M Q4 '23: -15.1M Q1 '24: -19.5M Q2 '24: -15.2M Q3 '24: -21.1M Q4 '24: -30.8M Q1 '25: -41.2M Q2 '25: -52.6M Q3 '25: -55.8M Q4 '25: -71.1M Q1 '26: -55.9M Q2 '26: -52.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-90M -60M -30M 0 30M 60M 90M Q3 '21: -62M Q4 '21: -70.5M Q1 '22: -69.1M Q2 '22: -73M Q3 '22: -71M Q4 '22: -54.4M Q1 '23: -33.1M Q2 '23: -22.6M Q3 '23: -12.1M Q4 '23: -7.9M Q1 '24: -28.8M Q2 '24: -25.7M Q3 '24: -35.2M Q4 '24: -44.1M Q1 '25: -54.2M Q2 '25: -65M Q3 '25: -69M Q4 '25: -83.8M Q1 '26: -68.9M Q2 '26: -78.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 8M 16M 24M Q3 '20: 17M Q4 '20: 13M Q1 '21: 12.1M Q2 '21: 13M Q3 '21: 14.4M Q4 '22: 19.4M Q1 '23: 19.9M Q2 '23: 21.3M Q3 '23: 21.5M Q4 '23: 20.8M Q1 '24: 20.5M Q2 '24: 18.4M Q3 '24: 18M Q4 '24: 17.9M Q1 '25: 17.1M Q2 '25: 17.2M Q3 '25: 17.2M Q4 '25: 18.6M Q1 '26: 18.4M Q2 '26: 17.8M Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-60M -40M -20M 0 20M 40M 60M Q3 '21: -38.4M Q4 '21: -33M Q1 '22: -33.4M Q2 '22: -38.2M Q3 '22: -26.3M Q4 '22: -9.8M Q1 '23: 13.5M Q2 '23: 12.1M Q3 '23: 7M Q4 '23: -6.4M Q1 '24: -25.6M Q2 '24: -24.7M Q3 '24: -34.2M Q4 '24: -35.8M Q1 '25: -48.8M Q2 '25: -49.7M Q3 '25: -50.5M Q4 '25: -52.4M Q1 '26: -43.8M Q2 '26: -45.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-60M -40M -20M 0 20M 40M 60M Q3 '21: -39M Q4 '21: -33.9M Q1 '22: -34.3M Q2 '22: -39.6M Q3 '22: -27.8M Q4 '22: -10.8M Q1 '23: 12.6M Q2 '23: 11.1M Q3 '23: 6M Q4 '23: -7.4M Q1 '24: -26.6M Q2 '24: -24.9M Q3 '24: -34.4M Q4 '24: -35.9M Q1 '25: -49M Q2 '25: -50M Q3 '25: -50.9M Q4 '25: -53M Q1 '26: -44.3M Q2 '26: -45.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q3 '19: 25M Q1 '20: 33.6M Q3 '20: 33.6M Q1 '21: 35.6M Q2 '21: 37.1M Q3 '21: 39.2M Q1 '22: 41.5M Q2 '22: 45.5M Q3 '22: 53.4M Q1 '23: 73.8M Q2 '23: 57.4M Q3 '23: 64.7M Q1 '24: 73.6M Q2 '24: 90.9M Q3 '24: 91.1M Q1 '25: 95.5M Q2 '25: 99.3M Q3 '25: 110.6M Q1 '26: 122.6M Q2 '26: 125M Q1 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.10 -1.40 -0.70 0.00 0.70 1.40 2.10 Q3 '21: -1.72 Q4 '21: -1.84 Q1 '22: -1.75 Q2 '22: -1.78 Q3 '22: -1.64 Q4 '22: -1.13 Q1 '23: -0.70 Q2 '23: -0.44 Q3 '23: -0.24 Q4 '23: -0.15 Q1 '24: -0.43 Q2 '24: -0.36 Q3 '24: -0.46 Q4 '24: -0.52 Q1 '25: -0.59 Q2 '25: -0.70 Q3 '25: -0.71 Q4 '25: -0.79 Q1 '26: -0.62 Q2 '26: -0.66 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.